Repligen Agrees to Buy BioLife in $1.5 Billion Cash-and-Stock Deal

Overview

• Repligen and BioLife announced the definitive agreement Wednesday, July 22, that values BioLife at about $1.5 billion and will pay shareholders $11.25 in cash plus 0.1442 Repligen shares per BioLife share.
• Both companies’ boards unanimously approved the transaction and the deal remains subject to BioLife shareholder approval, customary regulatory clearances and completion of SEC filings with a planned close in Q4 2026.
• Repligen projects the deal will be accretive to adjusted earnings per share by at least $0.05 in year one and $0.25 in year two and expects at least $20 million of cost synergies in year one and $30 million in year two.
• Each company reported preliminary, unaudited Q2 results that indicate continued growth, with Repligen noting roughly 12% reported revenue growth and BioLife reporting about $28.5 million in Q2 revenue, up 21% year‑over‑year.
• The acquisition gives Repligen immediate entry into the fast‑growing cell and gene therapy space by adding CryoStor and cell‑processing consumables used in many approved therapies and trials, which could broaden Repligen’s global reach and recurring revenue base.